Assessment of haemoglobin a1c evolution using two statistical approaches (survival analysis and linear regression) in persons with diabetes mellitus.

Department of Biophysics, Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic.
Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia (Impact Factor: 0.99). 06/2009; 153(2):137-43. DOI: 10.5507/bp.2009.023
Source: PubMed

ABSTRACT Intensive selfmonitoring is an important and cost-demanding part of diabetes treatment. Continuous glucose monitoring (CGM) using transcutaneous sensors offers "real time" information on glycemia. In the present study, we assessed the therapeutic efficacy of CGM on metabolic control using two different statistical methods: linear regression and "survival analysis".
(1) to assess the therapeutic efficacy of CGM on metabolic control using two different statistical methods: linear regression and survival analysis; (2) to demonstrate the particular advantages of each statistical method.
A total of 42 persons with diabetes mellitus treated by means of an insulin pump participated in this study. According to the means of selfmonitoring persons with diabetes were divided into two groups: 1. intervention group of 17 persons using CGM, 2. control group of 25 persons using a glucometer. Each person was followed for a period of three months. At the beginning of the study and at the end of each month HbA1c was determined.
Both the regression analysis and survival analysis brought evidence of significant changes of the HbA1c in either of the groups. The method of linear regression enables to analyse the evolution of HbA1c in each individual person followed by comparison of the groups. The survival analysis demonstrated that the probability of HbA1c decrease to the predefined level as well as its further maintaining at this level was higher in the CGM group. The mean time interval necessary to HbA1c decrease was shorter in the CGM group.
The efficacy of CGM was demonstrated. In addition to linear regression, survival analysis appears to be an useful complementary method in the statistical evaluation of the treatment efficacy.

1 Bookmark
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The purpose of this prospective open-label trial was (1) to assess the influence of oral antidiabetic drugs (OAD) on the glycemic index (GI), glucose response curves (GRCs), daily mean plasma glucose (MPG) and (2) to compare the GI of foods in persons with OAD-treated type 2 diabetes mellitus (T2DM) with the respective GI in healthy persons (HP). Tested foods containing 50 g of carbohydrates were eaten for breakfast and dinner after 10 and 4 h of fasting, respectively. Glycemic index, GRC, and MPG were obtained using the CGMS System Gold (CGMS). In T2DM patients [n = 16; age (mean +/- standard error) 56.0 +/- 2.25 years], foods were tested four times: tests 1, 2, and 3 were performed within one week in which placebo was introduced on day 2, and test 4 was carried out five weeks after reintroduction of OAD. Glycemic indexes, GRC, and MPG from tests 1, 2, 3, and 4 were compared. In a control group of 20 HP (age 24.4 +/- 0.71 years), the mean GIs were calculated as the mean from 20 subject-related GIs. In T2DM patients, subject-related assessment of GIs, GRC, and MPG distinguished persons with and without OAD effect. Nevertheless, the group-related GIs and the MPG on days 2, 8, and 39 showed no significant difference. There was no significant difference between the GIs in OAD-treated T2DM patients (test 4) versus HP (except in apple baby food). Glucose response curves were significantly larger in T2DM patients (test 4) versus HP. Determination of GRC and subject-related GI using the CGMS appears to be a potential means for the evaluation of efficacy of OAD treatment. Further studies are underway.
    Journal of diabetes science and technology 07/2010; 4(4):983-92.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Aim of the present prospective study was to assess the potential benefits of complementary insulin therapy, consisting of a single dose of 1 to 8 units of shortacting insulin before each meal, on blood glucose, serum lipid parameters and on patient's well-being. A group of 251 type 2 (non-insulin-dependent) diabetic patients completed the study. The complementary insulin therapy was introduced in hospital in the course of one week. Number of injections per day was increased, the average dose of insulin per day and the average dose of glibenclamide decreased, amount of carbohydrates in food (adapted by patients themselves) diminished, mean blood glucose, number of hyperglycaemia's and number of hypoglycaemia's decreased. At a check-up 8 to 10 weeks later, a decrease of haemoglobin A1c, glycated proteins in serum and body mass index together with improved patient's well-being have been shown. These results demonstrate a good effectiveness of complementary insulin therapy in type 2 (non-insulin-dependent) diabetic patients. We assume this kind of therapy should be more often recommended.
    Experimental and Clinical Endocrinology & Diabetes 02/1997; 105 Suppl 2:70-3. · 1.56 Impact Factor
  • Source
    07/2014; Klin Farmakol Farm(2014;28(2):72-79).

Full-text (2 Sources)

1 Download
Available from